S
14.32
0.15 (1.06%)
| 前收盘价格 | 14.17 |
| 收盘价格 | 13.61 |
| 成交量 | 1,021,642 |
| 平均成交量 (3个月) | 2,458,748 |
| 市值 | 1,222,322,176 |
| 价格/销量 (P/S) | 72.26 |
| 股市价格/股市净资产 (P/B) | 3.28 |
| 52周波幅 | |
| 利润日期 | 25 Feb 2025 - 3 Mar 2025 |
| 营业利益率 (TTM) | -716.62% |
| 稀释每股收益 (EPS TTM) | -3.64 |
| 总债务/股东权益 (D/E MRQ) | 0.23% |
| 流动比率 (MRQ) | 6.99 |
| 营业现金流 (OCF TTM) | -258.86 M |
| 杠杆自由现金流 (LFCF TTM) | -142.71 M |
| 资产报酬率 (ROA TTM) | -48.67% |
| 股东权益报酬率 (ROE TTM) | -81.88% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Syndax Pharmaceuticals, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
2.1
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.13 |
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.81% |
| 机构持股比例 | 106.20% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Kynam Capital Management, Lp | 30 Sep 2024 | 5,842,925 |
| Eversept Partners, Lp | 30 Sep 2024 | 4,105,313 |
| Avidity Partners Management Lp | 30 Sep 2024 | 2,455,000 |
| Assenagon Asset Management S.A. | 31 Dec 2024 | 2,064,456 |
| Orbimed Advisors Llc | 30 Sep 2024 | 1,925,300 |
| Woodline Partners Lp | 30 Sep 2024 | 1,896,032 |
| Stempoint Capital Lp | 30 Sep 2024 | 1,731,191 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 51.00 (HC Wainwright & Co., 256.15%) | 购买 |
| 中 | 38.00 (165.36%) | |
| 低 | 16.00 (Scotiabank, 11.73%) | 保留 |
| 平均值 | 36.60 (155.59%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 16.33 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Scotiabank | 08 Jan 2025 | 16.00 (11.73%) | 保留 | 13.81 |
| HC Wainwright & Co. | 10 Dec 2024 | 51.00 (256.15%) | 购买 | 14.94 |
| 18 Nov 2024 | 51.00 (256.15%) | 购买 | 16.11 | |
| JP Morgan | 21 Nov 2024 | 38.00 (165.36%) | 购买 | 15.60 |
| Citigroup | 19 Nov 2024 | 45.00 (214.25%) | 购买 | 15.77 |
| Goldman Sachs | 07 Nov 2024 | 33.00 (130.45%) | 购买 | 21.52 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合